Shots:

• The companies partnered to form JV focusing on the marketing- market access- and medical affairs activities for the IV iron portfolio. Vifor Pharma will own 55% while the Fresenius Kabi retains 45% of the new JV and is responsible for the commercialization of IV iron portfolio in China
• The new JV will combine Vifor’s iron deficiency portfolio with Fresenius Kabi’s commercial presence in China and will focus on patient blood management (PBM) benefiting patients and HCPs
• Vifor Pharma’s IV iron therapies are an innovative therapeutic option- allowing the effective management of patient’s blood and are used to treat IDA and other therapeutic areas

Click here ­to­ read full press release/ article | Ref: Vifor Pharma | Image: Global pharma update